Short answer
Adicet Bio Inc (ACET) filed its Q1 2019 10-Q quarterly report on May 15, 2019 for the quarter ended Mar 31, 2019.
Adicet Bio Inc Q1 2019 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, company has never generated product revenue
- Net loss $11.1M vs $9.9M YoY, operating margin not applicable due to no revenue
- Research and development expenses $8.9M vs $8.1M, highest spending area
- Cash, cash equivalents and marketable securities $143.1M; operating cash use $12.0M vs $7.3M YoY
- March offering generated $46.6M net; cash expected to fund operations through 2020, additional financing required
Risk Factors
- Newly added real-estate risk: relocation to 9,501-square-foot thirteenth-floor premises beginning August 1, 2019
- Financial risk: letter-of-credit requirement increased to $245,442.50
- Operational risk: original premises surrender required within five business days after relocation commencement
- Cost risk: annual base rent escalates from $589,062.00 to $663,379.49 over seven lease years
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Adicet Bio Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.